Vitrivax Announces Series A Financing To Further Demonstrate Feasibility Of Its Thermostable, Single-dose Vaccine Technology, Aiming To Make Life-saving Biologics Widely Accessible To Underserved Populations Globally
BOULDER, Colo., July 7, 2021 /PRNewswire/ -- VitriVax, developer of a novel stabilization and delivery platform for vaccines and therapeutics, today announced it has closed its first institutional financing round with Adjuvant Capital. Series A proceeds will be used to develop and...
In this article
No tags related to this article.